Showing results (461-470 of 887) with videos related to

Sort By:
Pageof 89
Clinical Journal of the American Society of Nephrology : CJASN|September 30, 2020
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational TrialAdeera Levin, Vlado Perkovic, David C Wheeler, et al.
Clinical Kidney Journal|September 26, 2022
Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitusFabian Hammer, Bernd Genser, Benjamin Dieplinger, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 3, 2022
Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis PatientsZiad A Massy, Thomas Merkling, Sandra Wagner, et al.
Artificial Organs|November 14, 2012
Bisphenol A in chronic kidney diseaseDetlef H Krieter, Bernard Canaud, Horst-Dieter Lemke, et al.
Kidney International|March 23, 2012
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockersHiddo J Lambers Heerspink, Frank A Holtkamp, Hans-Henrik Parving, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 21, 2011
Bone alkaline phosphatase and mortality in dialysis patientsChristiane Drechsler, Marion Verduijn, Stefan Pilz, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trialChristoph Wanner, Silvio E Inzucchi, Bernard Zinman, et al.
Clinical Therapeutics|September 27, 2016
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes MellitusTim Heise, Jens Jordan, Christoph Wanner, et al.
European Heart Journal|February 25, 2005
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the diseaseFrank Weidemann, Frank Breunig, Meinrad Beer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 13, 2017
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on HemodialysisChristiane Drechsler, Salim S Hayek, Changli Wei, et al.
Pageof 89